Clinical trials: Tumor Immunity
Haematological Malignancies
Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)
The purpose of this study is to evaluate whether the administration of allodepleted donor T cells to patients with haematological malignancies after stem cell transplant can improve the recovery of the patients immune system.
- Trial name
- ICAT (NCT01827579)
- Testing
- CD25/71 allodepleted donor T-cells
- Where
- 2 sites in United Kingdom
- Volunteers
- 37 people
- Sponsor
- University College, London
Solid Tumors, Adult
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
A phase 1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, antigen-specific immune response and preliminary antitumor activity associated with VB10.NEO administered in combination…
- Trial name
- NCT05018273
- Testing
- VB10.NEO
- Where
- 12 sites in United States, Germany and 1 more
- Volunteers
- 26 people
- Sponsor
- Nykode Therapeutics ASA
Psychological Stress
Health SMART (Stress Management and Relaxation Training) to Improve Vaccine Immune Response
The proposed investigation will conduct a randomized, clinical trial to test the efficacy of a cognitive behavioral stress management (CBSM) group intervention on immune response to vaccine and distress among women at elevated…
- Trial name
- NCT00121160
- Testing
- Cognitive Behavioral Stress Management (CBSM) group intervention
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Head and Neck Squamous Cell Carcinoma
Immune Response Evaluation to Curative Conventional Therapy
The IRECT trial is a non-interventional, prospective clinical trial using modern immune monitoring techniques over the course of the standard of care for HNSCC.
- Trial name
- IRECT-01 (NCT03053661)
- Volunteers
- 22 people
- Sponsor
- University of Ulm
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study…
- Conditions
- Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT04683679
- Testing
- Pembrolizumab, Olaparib, Radiation
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatitis B, Hepatitis C
Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants
The prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in the United States (US) is relatively low. However, immigrant populations in the US from Asia and sub-Saharan Africa have substantially higher prevalence…
- Conditions
- Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular
- Trial name
- NCT02366286
- Where
- United States
- Volunteers
- 892 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
NK Cell Mediated Immunity, NK Cell Cytokine Production
Cellular Immunity and Renal Cell Cancer
Renal cell cancer (RCC) is one of the most important urogenital tumors because of it's high mortality and increasing incidence. RCC, which accounts about 3% of all malignant tumors in the adults, is the most lethal urogenital…
- Conditions
- NK Cell Mediated Immunity, NK Cell Cytokine Production, Kidney Cancer
- Trial name
- NCT04377113
- Where
- Croatia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Clinical Hospital Center Rijeka
Meningococcal Meningitis, Human Papillomavirus Infection
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents
- Conditions
- Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis, Tetanus
- Trial name
- NCT00518180
- Testing
- Novartis Meningococcal ACWY Conjugate Vaccine, Tdap Vaccine
- Where
- Costa Rica
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Immunity, Innate, Colorectal Cancer
Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy
This study will measure the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in high risk subjects (Quebec risk categories P2, P3 and P4) scheduled for colonoscopy.
- Trial name
- ANKA-HR (NCT03249727)
- Testing
- IVDD for NK cell activity in whole blood
- Where
- 3 sites in Canada
- Volunteers
- 396 people
- Sponsor
- ATGen Canada Inc
Renal Failure Chronic Requiring Dialysis
Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients
Cell-mediated immunity (CMI) and in particular T cells play a critical role in the rejection of transplanted organs. Thus, in transplant recipients a life-long and individualized immunosuppressive medication is required to avoid…
- Trial name
- NCT02630537
- Volunteers
- 133 people
- Sponsor
- Lophius Biosciences GmbH
2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma
- Trial name
- ECLIPSE (NCT02004262)
- Testing
- GVAX Pancreas Vaccine, CRS-207, Chemotherapy
- Where
- 21 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- Aduro Biotech, Inc.
Metastatic Malignant Solid Neoplasm, Lymphoma
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
"This phase I trial investigates the effect of radiation therapy on the immune system, specifically CD8 positive (+) T cells, in lymphoma patients receiving bridging radiation therapy before CAR T-cell infusion, and metastatic…
- Trial name
- NCT05371132
- Testing
- Positron Emission Tomography, Stereotactic Body Radiation Therapy, Zirconium Zr 89-Df-Crefmirlimab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Colorectal Surgery
Effects of Postoperative Pain Management on Immune Function After Laparoscopic Resection of Colorectal Cancer
The purpose of this study is to compare postoperative immune function (e.g. NK cell activity) of fentanyl-based analgesic regimen versus local anesthetic wound infiltration-based anlagesic regimen after laparoscopic colorectal…
- Trial name
- NCT02012244
- Testing
- fentanyl-based analgesia, local anesthetic wound infiltration-based anlagesia
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Severance Hospital
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
This randomized pilot phase II trial studies the effect of pembrolizumab with or without carboplatin and paclitaxel on immune response in patients with non-small cell lung cancer that has come back or stage IIIB-IV.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02581943
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Wake Forest University Health Sciences
Colorectal Adenocarcinoma, Mucinous Adenocarcinoma
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
Hypothesis: Patients with metastatic colorectal cancer with DNA mismatch repair-proficient (pMMR) function / microsatellite-stable (MSS) phenotype harbor a non-immunogenic disease that can be transformed into an immunogenic…
- Conditions
- Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma
- Trial name
- METIMMOX-2 (NCT05504252)
- Testing
- Nivolumab, Oxaliplatin
- Where
- 3 sites in Norway
- Volunteers
- 80 people
- Sponsor
- University Hospital, Akershus
Pancreatic Cancer Resectable
Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures
Prospective inclusion of 1000 patients with pancreatic cancer (early-stage pancreatic cancer accounts for approximately 75% of cases), 1000 patients with benign pancreatic diseases, and 1000 healthy individuals as controls.
- Trial name
- NCT06495749
- Where
- 2 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
Cervical Cancer
Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy
Perspectives: To set-up another clinical trial with this specific phenotype as the main stratification factor. Therefore a more aggressive or a more specific systemic treatment (with or without an immunomodulator) could be…
- Trial name
- IMMUVIX (NCT03255252)
- Testing
- Cisplatin injection, radiotherapy
- Where
- 3 sites in France
- Volunteers
- 29 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Esophageal Carcinoma Salivary Gland Type, Radiotherapy
The Study on the Mechanism of Radiotherapy-elicited Immune Response
Radiotherapy plays an important role in multidisciplinary treatment of esophageal cancer. Data from many laboratories indicate that local radiation produces systemic, immune-mediated anti¬tumour and, potentially, antimetastatic…
- Trial name
- NCT06393140
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Colorectal Cancer
Safety and Immune Response to FMPV-1
This is a single centre, open-label, non-randomized, Phase I study assessing safety and immune response of FMPV-1 in healthy male subjects.
- Trial name
- NCT05238558
- Testing
- FMPV-1, GM-CSF (as adjuvant)
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hubro Therapeutics AS
Metastatic Breast Cancer
Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422)
In the last few years there has been a great attempt to develop active immunotherapies for breast cancer patients (BCPs) using undefined as well as selected antigens to activate tumor specific T-lymphocytes.
- Trial name
- KS2422-vacc (NCT01127074)
- Testing
- KS24.22 cells
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital Tuebingen